Nomura Holdings
MIST icon

Nomura Holdings’s Milestone Pharmaceuticals MIST Stock Holding History

Nomura Holdings’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-225,000
Closed -$455K – 1964
2025
Q4 		$455K Buy
+225,000
New +$485K ﹤0.01% 1553

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Nomura Holdings's MIST Position: Q1 2026 in Review

Nomura Holdings sold out of Milestone Pharmaceuticals (MIST) in Q1 2026, closing a stake of 225,000 shares — an estimated $455K sold.

Nomura Holdings first reported a position in MIST in Q4 2025 and held it in 1 quarter. The position peaked at $455K in Q4 2025. 86 funds tracked by Wall St. Rank hold MIST as of Q1 2026.

  • Nomura Holdings reported no remaining Milestone Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Nomura Holdings sold 225,000 Milestone Pharmaceuticals shares in Q1 2026, an estimated $455K.
  • Nomura Holdings first reported a position in Milestone Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Nomura Holdings's Milestone Pharmaceuticals position peaked at $455K in Q4 2025.
  • 86 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q1 2026.

Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.